HeartFlow Reports Strong Q3 2026 Results with 57% Revenue Growth and Raised Full-Year Guidance
HeartFlow (HTFL) delivered robust third-quarter 2026 financial results, headlined by $72.9 million in revenue, a 57.4% increase year-over-year. This growth was primarily driven by the rapid adoption of its Plaque Analysis platform and record domestic demand in the U.S., where revenue grew by 60%. The company also reported significant margin expansion, with non-GAAP gross margins reaching 83.8% due to volume leverage and AI-driven efficiencies. Driven by strong performance, management raised its full-year revenue guidance to a range of $262 million to $264 million. The company is successfully narrowing its operating losses while maintaining a healthy cash position of $253 million, which it believes is sufficient to reach cash flow profitability. Clinical data from the DECIDE registry further supports market expansion, showing a 34% reduction in major cardiovascular events for patients using HeartFlow's technology.
Tickers: $HTFL
Topics: gross margin expansion guidance increase plaque analysis platform revenue growth